OctoPlus announces positive Phase IIa efficacy and tolerability results for Locteron in hepatitis C
Advertisement
OctoPlus N.V. announced the successful completion of the Phase IIa clinical study with its lead product Locteron(TM), a controlled release interferon alfa product for the treatment of chronic hepatitis C (HCV).
According to the company, results from this study confirm Locteron's potential to substantially improve patient care in HCV. Safety data from the study show a substantially improved tolerability profile for Locteron compared to other interferon products on the market or in development. Efficacy data from the study indicate Locteron's strong antiviral effect, with 100% of the patients achieving early virologic response in the two highest dose groups. In addition, Locteron is a more convenient therapy than existing treatments due to its controlled-release profile, allowing for once every two weeks drug administration versus the current once a week regimen. OctoPlus is co-developing Locteron with its partner Biolex Therapeutics.
Locteron is designed to be a best-in-class therapeutic for patients with chronic hepatitis C, with the potential to induce less side effects, improve patient compliance and provide a more convenient once every two week dosing schedule compared with current therapies. Locteron combines OctoPlus' proprietary PolyActive(TM) drug delivery technology with BLX-883, a recombinant interferon alfa produced by OctoPlus' co-development partner Biolex Therapeutics in its patented LEX System(SM). Locteron is produced in OctoPlus' cGMP manufacturing facilities in Leiden, the Netherlands.
Other news from the department research and development
Most read news
More news from our other portals
Last viewed contents
NeuroVive and to-BBB awarded Eurostars grant for development of stroke therapy
Oxford Nanopore Announces Licence Agreement with Harvard University for Graphene DNA sequencing
to-BBB starts manufacturing collaboration with TTY Biopharm for brain cancer treatment
HealthLinx and InSymbiosis to co-develop therapeutic for lung disease
TxCell achieves positive results for Col-Treg in a model of autoimmune uveitis
Genomatix Wins BioChance Grant for $1.6 Mio Research Project into RNAi Mediated Regulatory Networks
Clearbridge BioMedics makes a big impact at the 2012 Asian Innovation Awards
Kansas State University professor's USDA research shows mad cow disease also caused by genetic mutation
BASF applies for European approval for Fortuna, a disease-resistant table potato
